+

WO1988003170A1 - Proteines associees a des agents tensioactifs hydrophobes pulmonaires - Google Patents

Proteines associees a des agents tensioactifs hydrophobes pulmonaires Download PDF

Info

Publication number
WO1988003170A1
WO1988003170A1 PCT/US1987/002536 US8702536W WO8803170A1 WO 1988003170 A1 WO1988003170 A1 WO 1988003170A1 US 8702536 W US8702536 W US 8702536W WO 8803170 A1 WO8803170 A1 WO 8803170A1
Authority
WO
WIPO (PCT)
Prior art keywords
val
sap
leu
pro
phe
Prior art date
Application number
PCT/US1987/002536
Other languages
English (en)
Inventor
Jeffrey A. Whitsett
J. Lawrence Fox
Tami J. Pilot-Matias
Joseph L. Meuth
Virender K. Sarin
Original Assignee
Whitsett Jeffrey A
Fox J Lawrence
Pilot Matias Tami J
Meuth Joseph L
Sarin Virender K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1986/002258 external-priority patent/WO1987006943A1/fr
Application filed by Whitsett Jeffrey A, Fox J Lawrence, Pilot Matias Tami J, Meuth Joseph L, Sarin Virender K filed Critical Whitsett Jeffrey A
Publication of WO1988003170A1 publication Critical patent/WO1988003170A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Definitions

  • the present application relates to pulmonary hydrophobic surfaction associated proteins ("SAPs”) and methods for the isolation and use thereof.
  • SAPs pulmonary hydrophobic surfaction associated proteins
  • SAP(Val) methods for isolation thereof and methods for the use thereof.
  • Hyaline membrane disease is a common disorder of premature infants and is related to diffuse atelectesis, hypoxia and resultant respiratory impairment. More particularly, HMD relates to the lack of vital pulmonary materials necessary for reducing surface tension in the airways of the alveoli. As a result, the alveoli or terminal respiratory sacs of patients suffering from HMD normally collapse. And, because the surface tension at the gas-liquid interface in HMD patients is elevated, their alveoli or terminal respiratory sacs are very difficult to reinflate. Consequently, HMD may be associated with significant morbidity and mortality, especially in premature infants.
  • ARDS adult respiratory distress syndrome
  • syndromes associated with a lack of pulmonary surfactant material include any chronic obstructive pulmonary diseases, pneumonia or other conditions resulting in damage to pulmonary type II cells.
  • Therapy for syndromes associated with a lack of pulmonary surfactant material may include the use of aerosolized or liquid synthetic phospholipid mixtures, natural pulmonary surfactant material and various preparations of surfactant material prepared from animal lung.
  • the surface tension lowering ability of naturally derived preparations is in general better than that of synthetic lipid preparations.
  • Modified bovine surfactants are also proposed for use in such preparations.
  • problems with human and animal pulmonary preparations include batch-to-batch variability and possible infection and immunologic risks.
  • Natural pulmonary surfactant is a complex material composed primarily of phospholipids and surfactant-associated proteins or apolipoproteins.
  • the phospholipids mainly phosphatidycholine (“PC"), disaturated phosphatidycholine (“DSPC”) and phosphatidylglycerol (“PG”), are of paramount importance for the physiological role of natural pulmonary surfactant material in reducing surface tension in the alveoli.
  • Phospholipids of which DSPC is the principal component, are synthesized in the endoplasmic reticulum of Type II epithelial cells, packaged into lamellar bodies, then secreted into the alveolar space by an exocytotic process. It is believed that several of the phospholipids are not catabolized and resynthesized, but that they are reutilized, primarily as intact molecules, and that they constitute the major components of the natural pulmonary surfactant material.
  • Surfactant-associated proteins or apolipoproteins include both serum- and lung-specific proteins.
  • the major lung specific surfactant-associated protein of M r 30-40,000 daltons is identified in lung surfactant by King et al., Am. J. Physiol., 244, 788-795 (1973), is a glycoprotein which is rich in glycine and which contains a collagen-like region rich in hydroxyproline.
  • Proteolytic fragments of SAP-35 are found in protein preparations isolated from lavage of patients with alveolar proteinosis and from other mammalian surfactants migrating as proteins of small molecular weight [Whitsett et al., Pediatr. Res., 19, 501-508 (1985)]. While the glycoprotein SAP-35 binds phospholipids and may confer the structural organization of tubular myelin to surfactant lipids, SAP-35 may not be required for the biophysical activity of surfactants. See King et al., J. Appl. Physiol., 42, 483-491 (1977).
  • Smaller lung specific surfactant-associated proteins are also identified from a variety of mammalian surfactants.
  • a 10,000-12,000 dalton protein may be present in pulmonary surfactant material [King et al., Am. J. Physiol, 223, 715-726 (1972)]. This protein is now believed to be a fragment of the major glycoprotein SAP-35.
  • Smaller surfactant-associated proteins may be present in alveolar lavage material from a number of species and may have molecular weights of approximately 10,000 daltons in the dog and the rabbit, 10,500-14,000 daltons in the rat, 11,500-16,500 daltons in the pig, and 10,000 daltons in the cow.
  • a small SAP protein is reported to be isolated from rat alveolar lavage by isolation methods involving ether/ethanol treatment, chloroform/methanol extraction, and chloroform/methanol elution from a silicic acid column, and is reported to increase the uptake of liposome by cultured Type II epithelial cells [Claypool et al., J. Clin. Invest., 74, 677-684 (1984)].
  • Fujiwara et al. Biochem., Biophys. Res. Comm., 135, 527-532 (1986), reports the isolation of a 5,000 dalton molecular weight proteolipid which, based on biophpysical testing, may have surface activity when mixed with phospholipids.
  • this protein is not well-characterized in Fujiwara et al.
  • Schilling et al. PCT Application No. WO86/03408, a human 35,000 dalton protein and nonhuman 10,000 dalton proteins are described. Schilling et al. indicates that both classes of proteins may be needed to confer full biophysical activity upon surfactant phospholipids. Schilling et al. also discloses a complete DNA sequence encoding the 35 , 000 dalton protein, NH 2 -terminal amino acid sequences for the 10,000 dalton nonhuman proteins and a preliminary (81 bp) partial sequence for a human cDNA clone for the 10,000 dalton protein. The 10,000 dalton canine and 81 bp human sequences have substantial regions indentical in sequence to the sequence of human SAP(Phe) according to the present invention.
  • Monoclonal antibodies raised against alveolar surfactant protein are disclosed in Lewicki, U.S. Patent No. 4,562,003.
  • Hydrophobic small molecular weight proteins soluble in organic solvents are detectable in a variety of mammalian surfactants [Phizackerly et al., Biochem. J., 183, 731-736 (1979); Tanaka et al., Chem. Pharm.
  • SAPs identifiable as proteins of M r 6,000-14,000 are identified in the etherethanol extracts of surfactant preparations used clinically for treatment of hyaline membrane disease [Whitsett et al., Pediatr. Res., 20, 460-467 (1986); Whitsett et al., Pediatr Res., 20, 744-749 (1986); Fujiwara et al., Lancet, 1 , 55-59 (1980); Enhorning et al., Pediatrics, 76, 145-153 (1985); and Kwong et al., Pediatrics, 76, 585-592 (1985)].
  • cDNA encoding a protein homologous to SAP(Phe), SP-18 is reported to be isolated from canine lung [Hawgood et al., Proc. Nat'l Acad. Sci.
  • SAP(Val) and SAP(Phe) are isolated, substantially pure, hydrophobic surfactant-associated proteins of 4,000-7,000 dalton simple molecular weight which, when isolated from animal tissue, comprise at least two hydrophobic proteins of molecular weights of 4,000-7,000 daltons each and may also comprise larger multimers thereof.
  • SAP(Val) is also referred to in publications as “SAP-6(Val),” as SPL(pVAL)” and as “SP-C.”
  • SAP(Phe) is referred to in publications as “SAP-6(Phe),” “SPL-(Phe)” and “SP-B.”
  • SAP(Val) and SAP(Phe) when combined with lipids, have significant pulmonary biophysical surfactant activity that may be utilized to effectively treat and prevent HMD and other syndromes associated with lack or insufficient amounts of natural pulmonary surfactant material.
  • SAP(Val) and SAP(Phe) are lung-specific, their pulmonary biophysical surfactant activity is believed not to be species-specific. Therefore, SAP(Val) and SAP(Phe) may be purified from animal tissue, specifically pulmonary tissue or amniotic fluid, extracted from a variety of animals, such as dog, cow, human, pig, rabbit, rat and the like, or made by recombinant DNA methods or direct peptide synthesis.
  • SAP(Val) and SAP(Phe) concentration of SAP(Val) and SAP(Phe) in pulmonary tissue and lavage is probably greater than that found in aminotic fluid. With respect to other animal tissues or fluid, however, SAP(Val) and SAP(Phe) are believed to be present in substantially smaller or undetectable concentrations or completely absent.
  • SAP(Val) and SAP(Phe) may be highly purified from animal tissue, or made by recombinant DNA techniques or by direct peptide synthesis, the immunologic risks currently associated with the less pure preparations available heretofore for treating or preventing HMD or related syndromes are substantially reduced.
  • hydrophobic surfactant-associated protein hydrophobic surfactant-associated protein
  • SAP(Val) or SAP(Phe) are used interchangeably herein, and that whenever referenced herein, they are meant to include any small hydrophobic surfactant-associated proteins having surfactant-like activity, having simple molecular weights of about 4,000-7,000 daltons determined in polyacrylamide gels containing sodium dodecyl sulfate and having substantial resistance to protease enzymes, endoglycosidase F and collagenase.
  • proteins or polypeptides having surfactant-like activity which are made by recombinant DNA methods or direct peptide synthesis comprising the amino acid sequences of such hydrophobic surfactant-associated proteins or translations of DNA sequences or portions thereof encoding such proteins, or deletion, substitution, or addition analogs of such proteins.
  • hybridization as used herein is meant to encompass conditions within a range of functional equivalents to and generally according to the conditions set forth in Examples 6, 7, 11, 12, 15 and 16.
  • the present invention further resides in a method of separating SAP(VaI) from animal tissue which involves separating the animal tissue into a particulate fraction and a liquid fraction, and extracting SAP(VaI) in a substantially pure state from the liquid fraction.
  • the methods substantially reduces risks currently associated with the less pure preparations available heretofore for treating or preventing HMD or related syndromes.
  • the methods of this invention are further concerned with separating SAP(VaI) from the larger, novel hydrophobic multimers thereof by, for instance, gel electrophoresis or other suitable techniques.
  • SAP(Val) and SAP(Phe) may also be made by recombinant DNA methods.
  • human lung poly(A) + RNA was used as a template to synthesize complementary DNA (cDNA) copies of which were subsequently cloned into a lambda vector in E.coli.
  • cDNA copies of the genes encoding SAP(Val) and SAP(Phe) were identified, and then characterized by DNA sequence analysis. These DNA sequences allowed for further characterization of SAP(Val) and SAP(Phe) by comparison with the amino acid sequences for both SAP(Val) and SAP(Phe).
  • the cDNA encoding SAP(Phe) was expressed as a fusion product with the E.coli ⁇ -galactosidase (lacZ) gene, and the resulting expressed gene product has been shown to be antigenic by reacting with polyclonal antisera specific for SAP(Phe).
  • Polypeptides may be made by chemical or enzymatic synthesis based on the sequences given herein including the NH 2 -terminal amino acid sequences given in Tables 2 and 3 and the translation of DNA sequences given in FIGS. 5 and 6. These chemically synthesized polypeptides include replicas of the amino acid sequences of SAP(Val) or SAP(Phe) or translations of DNA sequences encoding SAP(Val) or SAP(Phe) or portions of these sequences, as well as addition, deletion and substitution analogs of such replicas. The synthetic polypeptides may then be combined with lipids for surfactant preparations.
  • synthetic polypeptides may have a molecular weight less than SAP(Val) or SAP(Phe) isolated from animal tissue, it is to be understood that the terms "SAP(Val)” and “SAP(Phe),” as used herein, encompasses these synthetic peptides.
  • fragments of synthetic peptides having less than all, more particularly less than 75% and especially less than 50% of the coding region of SAP(Phe) or SAP(Val) are provided according according to the present inventor.
  • the present invention also includes novel medicaments, preparations, and methods employed to treat animals, including humans, suffering from HMD and other syndromes related to the lack or insufficient amounts of natural pulmonary surfactant material.
  • Antibodies and antisera according to the present invention may be made which are directed against SAP(Val) or SAP(Phe).
  • FIG. 1 is an illustration of an SDS-PAGE preparation of SAP(Val) isolated from bovine lung
  • FIG. 2 is an illustration of an SDS-PAGE preparation of SAP-6 from human, canine and bovine lung.
  • FIG. 3 is a nucleotide sequence and deduced amino acid translation of a partial cDNA clone encoding SAP(Phe);
  • FIG. 4 is a schematic depiction of the structure of SAP(Val) cDNA clones according to the present invention.
  • FIG. 5 is a nucleotide sequence and deduced amino acid translation of complete SAP(Val) cDNA
  • FIG. 6 is a nucleotide sequence and deduced amino acid translation of complete SAP(Phe) cDNA
  • FIG. 7 is a flow chart of the construction of a lacZ/SAP-6-Phe fusion product
  • FIG. 8A is an illustration of the organization of the SAP(Phe) gene and FIG. 8B is a nucleotide sequence of a genomic clone encoding of SAP(Phe);
  • FIG. 9 depicts restriction maps and illustrates the organization of two SAP(Val) genes;
  • FIG. 10 is a nucleotide sequence of a genomic clone encoding SAP(Val);
  • FIG. 11 is an illustration of a Northern blot of SAP(Val);
  • FIG. 12 is a depiction of results of a hybrid arrested translation of SAP(Val);
  • FIG. 13 is an illustration of an SDS-PAGE of CKS and CKS/SAP(Val) fusion protein
  • FIG. 14 is an illustration of a SDS-PAGE of CKS/SAP(Val) fusion protein after initial purification
  • FIG. 15 is a graph of SAP(Phe) concentration versus gestational age obtained from a competitive ELISA assay using polyclonal antibodies directed against SAP(Phe) of human amniotic fluid samples for predicting pulmonary maturation;
  • FIG. 16 is a hydropathy plot for the amino acid sequence of SAP(Val) precursor protein.
  • SAP(Val) isolated from animal tissues, specifically pulmonary tissue and amniotic fluid, or made by recombinant DNA methods or by direct peptide synthesis, as well as novel medicaments based on SAP(Val), novel antibodies and antisera and methods of preparation and utilization thereof.
  • SAP(Val) and SAP(Phe) monomers are isolated from animal tissue.
  • SAP(Val) and SAP(Phe) may also occur as larger, hydrophobic protein multimers which may be covalent or noncovalent aggregates of SAP(Val) and/or SAP(Phe) monomers having molecular weights of about
  • SDS-PAGE sodium dodecyl sulfatepolyacrylamide gel electrophoresis
  • SAP(Val) and/or SAP(Phe) multimers Other multimers or closely related peptides may exist but in smaller or undetectable concentrations.
  • simple molecular weight refers to the molecular mass of what is thought to be the smallest polypeptide chain after sulfhydryl reduction which serves as a repeating building block for such multimers.
  • FIG. 1 illustrates SAP(Val) purified and delipidated as described herein and applied to a 10-20% sodium dodecyl sulfate- polyacrylamide electrophoresis gel in the absence of ⁇ -mercaptoethanol.
  • low molecular weight protein markers such as trypsin inhibitor (6,200), lysozyme (14,000), ⁇ -lactalbumin (18,400), ⁇ - chymotrypsin (25,700) and ovalbumin (43,000) may be used. These may be obtained from BRL, Inc., of Bethesda, Maryland.
  • hydrophobic refers to solubility in non-polar solvents, such as 3:1 ether/ethanol, chloroform, chloroform/methanol in various ratios, such as 3:1, and having an abundance of hydrophobic non-charged amino acids.
  • surfactant-associated protein refers to proteins associated with binding to or co-purifying with the phospholipid components of mammalian surfactants during centrifugation in isotonic solution.
  • SAP(Val) and SAP(Phe) may be further characterized as being substantially resistant to protease enzymes (trypsin, chymotrypsin and staph V-8), endoglycosidase F, and collagenase. It has been discovered that SAP(Val) and SAP(Phe) are not degraded nor are their size heterogeneity significantly altered by these enzymes and therefore are distinct from SAP-35 and its fragments.
  • SAP(Val) and SAP(Phe) are localized in lung tissue and specifically in pulmonary type II cells and lung surfactant in a variety of mammalian species, as well as in human amniotic fluid near term gestation.
  • SAP(Val) may be purified from, for example, animal tissue and fluids, cells, cultivated cells, suitable pulmonary surfactant replacement preparations available, such as CLSE or Surfactant-TA, and the like.
  • animal tissue as used herein is meant in a broad sense to encompass all appropriate sources for SAP(Val), including but not limited to animal tissue and fluid, cells, cultivated cells, pulmonary surfactant replacement preparations, such as CLSE and Surfactant-TA, and the like.
  • isolating SAP(Val) from animal tissue it is preferred, however, to isolate SAP(Val) from animal pulmonary tissue or amniotic fluid, and more preferably human pulmonary tissue or cultured cells.
  • Solutions containing SAP(Val) are obtained by extraction of animal tissue in which SAP(Val) occurs.
  • the trachea preferably is cannulated and washed repeatedly with several volumes of an iced, buffered solution, such as 0.9% NaCl (pH 7.0-7.4), to remove surfactant from the alveoli.
  • the wash is centrifuged at low speed, for example, 1,000 x g for ten minutes, and is repeated, if necessary, to remove contaminating blood and white cells or macrophages. All procedures preferably should be performed at about 2-4°C.
  • This surfactant material should then be centrifuged at high speed from the alveoli wash to sediment particulate materials at about 10,000 x g for about 30 minutes or longer.
  • This pellet preferably should be resuspended and washed by repeated centrifugation and sonicated or freeze thawed, several times if necessary, in a suitable buffer, such as the one above, to uniformly resuspend the materials.
  • the resulting white surfactant is pelleted by centrifugation, the aqueous material is removed and the pellet is extracted with about 10-100 volumes of approximately 2:1 ether/ethanol, 3:1 chloroform/methanol or other suitable organic solvents at about -30°C to produce a supernatant containing SAP(Val). Extraction is carried out overnight. The material is then centrifuged at about 10,000 x g for about 20 minutes or longer. The resulting liquid fraction contains lipid and includes the SAP(Val) of this invention.
  • the liquid fraction thereafter may be dried (concentrated) with, for instance, N 2 stream, resuspended in an organic solvent, such as chloroform or other suitable organic solvents, and applied to a silicic acid column or LH-20 column approximately 50 cm x 2.5 cm in size which is pre-equilibrated with chloroform or other suitable organic solvents at room temperature.
  • the column is then eluted with, for example, 50 to 200 ml of a mixture of chloroform and alcohol, such as methanol or the like, increasing the alcohol concentration from 0% to about 100% in stepwise or gradient fashion.
  • SAP(Val) is eluted in the solvents containing alcohol having concentrations of greater than about 40% up to about 100% and more. particularly about 40% to about 80%.
  • lipids present in the SAP(Val) are separated from the proteins. Dialysis in chloroform/methanol or acidified (0.1 N HCl) chloroform/methanol further removes phospholipid and further purifies the protein. It should be appreciated to those skilled in the art that the silicic acid column may also be eluted with any other suitable solvents capable of extracting therefrom the SAP(Val) of this invention.
  • SAP(Val) is isolated from lung lavage material obtained from adult dogs and cows after sacrifice. SAP(Val) is also isolated from human surfactant which is obtained from human cadavers after autopsy or from lung lavage of consenting adults. In animals, the trachea is cannulated and the lung is lavaged three times with several volumes of iced 0.9% NaCl, 50 mM Na 2 HPO 4 , and 5 mM EDTA, pH 7.2. Cells and debris are removed by centrifugation at 80 x g for about 10 minutes (twice) and the supernatant is then centrifuged at 40,000 x g for about 30 minutes at 4°C.
  • the pelleted material is then resuspended in the above buffer with or without 1 mM phenylmethyl-sulfonylfluoride and sonicated for 10 seconds with a Branson sonifier.
  • Surfactant material is pelleted by repeated centrifugation at about 40,000 x g for about 30 minutes at 4°C.
  • the surfactant pellet is further processed by extraction in about 3:1 ether/ethanol or chloroform/methanol at about -30° C for about 16 hours.
  • Ether/ethanol or chloroform/methanol extracts containing SAP(Val) are evaporated to near dryness with N 2 gas and are redissolved in chloroform.
  • the redissolved residue in chloroform is applied to a BioSil-HA column (silicic column dimensioned 2.5 cm by 40 cm, obtained from Bio-Rad, Richmond, California) and is equilibrated in chloroform.
  • Lipid-protein fractions are recovered by stepwise elution with chloroform- methanol mixtures (200 ml each) with successive increases in concentration of methanol (10% intervals) in chloroform.
  • SAP(Val) is eluted between 3:2 and 1:4 chloroform/methanol solvent elution or about 40% to about 80% methanol in chloroform.
  • SAP(Val) proteins are substantially free of contaminants, such as cells, cellular debris, DNA, RNA, and major surfactant glycoproteins or fragments thereof. It should be appreciated, however, that some lipids still remain in the now substantially pure SAP(Val).
  • Dialysis at room temperature in 2% chloroform/methanol or acidified chloroform/methanol in cellulose dialysis bags having a 3,000 molecular size cutoff is useful for further delipidating SAP(Val).
  • the substantially pure SAP(Val) contains on the order of about 10% or less of contaminants.
  • the fractions containing the eluted SAP(Val) preferably are pooled, evaporated to near dryness and subjected to repeated dialysis in, for example, a cellulose dialysis bag with about 100-500 volumes of about 2:1 of chloroform/methanol or other suitable mixtures or acidified chloroform/methanol mixtures acidified with HCl or other appropriate acids at about room temperature.
  • This procedure should proceed until the SAP(Val) is virtually free of contaminating lipids.
  • This substantially purified SAP(Val) may again be assessed by fluorescamine assay and gel electrophoresis migration. It should be realized that other suitable delipidating steps may also be employed to accomplish the above delipidating objective.
  • the approximate amino acid composition also can now be determined and the proteins identified after PAGE with Coomassie brilliant blue, silver staining or other standard staining techniques.
  • purified samples are hydrolyzed by two different methods.
  • the samples are hydrolyzed in constantly boiling 5.7 N HCl containing 0.3% phenol and 0.1% ⁇ - mercaptoethanol at 110°C. under a vacuum for about 24 and 48 hours.
  • these same samples are hydrolyzed in 12 N HCl/trifluoroacetic acid (2:1) containing 0.3% phenol at 150°C under vacuum for 2 hours, 6 hours, 24 hours and 48 hours.
  • the cysteine composition of these samples is determined separately as cysteic acid after performic acid oxidation.
  • Table 1 illustrates the amino acid compositions determined for bovine and canine SAP(Val) using an amino acid analyzer. It should be understood to those skilled in the art that, because the amino acid compositions have been determined using a Beckman 6300 analyzer , the amino acid residue compositions, as reported per protein molecule in Table 1, are only estimates based upon this analytical technique. In fact/ because the compositions in Table 1 are generally divisible by 2 to obtain whole numbers, and because subsequent amino acid sequencing data account for about one-half of the residues reported in Table 1, it may be the case that the results reported therein represent a dimer of SAP(VaI), or at least represent twice the respective composition values for a SAP(VaI) monomer.
  • the sequences for the first 25, the first 23, and the first 19 NH 2 -terminal amino acid residues, respectively, for bovine, canine and human SAP(Val) have been determined and are shown in Table 2.
  • the sequences for the first 6, the first 7, and the first 14 NH 2 -terminal amino acid residues, respectively, for the bovine, canine and human SAP(Phe) have been determined and are shown in Table 3.
  • Amino acids having alternate amino acids in parenthesis underneath indicate alternative amino acids potentially determinable by the above procedure.
  • the human HN 2 -terminus is now believed to be Gly, but sequences having Gly, He or Leu as an NH 2 -terminus (potentially obtained as a result of variable proteolytic processing at the NH 2 -terminus) are comprehended in the term "human" SAP (Val).
  • Altex reversed-phase PTH-C 18 column A binary buffer system consisting of ammonium acetate and buffered acetonitrile, pH 4.5, is used.
  • the chromatography procedure is conducted utilizing buffer A which contains about 10% acetonitrile and buffer B which contains about 90% acetonitrile.
  • the initial chromatography conditions are 70% buffer A and 30% buffer B with a flowrate of 1.0 ml per minute.
  • concentration of buffer B is linearly increased to 50% over a 3 minute period and held at this level for 8 minutes.
  • concentration of Buffer B then is reduced to 30% over one minute.
  • re-equilibration which takes approximately 10 minutes, another PTH sample is injected.
  • SAP(Val) is subjected to gel electrophoresis migration in the absence of ⁇ -mercaptoethanol, a sulfhydryl reducing agent, major and minor amounts of protein appear. This may be better understood with reference to FIG.
  • SAP (Val) purified and delipidated as described herein, and applied to 10-20% sodium dodecyl sulfate- polyacrylamide electrophoresis gels in the presence of ⁇ -mercaptoethanol is illustrated. Each lane represents approximately 2 micrograms of each protein detected by silver staining.
  • Polyclonal rabbit antisera were raised against bovine surfactant proteolipid, prepared from chloroform/methanol extraction of bovine lung surfactant [see Notter et al., Chem. Phys. Lipids, 33, 67-80 (1980), and were preabsorbed to minimize nonspecific background to E. coli proteins in a screening procedure.
  • the preabsorption was done by the following procedure.
  • An E. coli strain Y1090 lysate was disrupted by treatment with EDTA (pH 8.0) followed by sonication on ice with six bursts from a Branson sonifier at 50 watts for 10 seconds each. The sonicate was centrifuged at low speed to clear the supernatant. This supernatant was incubated with the above antisera for 48 hours at 4°C, then centrifuged to remove antibody/antigen complexes.
  • the library was plated on E. coli strain Y1090 at 20,000 pfu per 150 mm dish, grown for 5 hours at 42°C. and then blotted to nitrocellulose filters soaked in 10 mM isopropylthiogalactoside (IPTG). Filters were incubated overnight at 37°C. and then blocked for 1 hour at 4°C. in 50 mM Tris HCl, pH 7.4, 150 mM NaCl (TBS), and 50 gm/L powdered milk. Primary antibody reactions were conducted at a dilution of 1:1000 by incubation with the filters at 4°C. overnight.
  • IPTG isopropylthiogalactoside
  • the filters were then incubated with horseradish peroxidase conjugated goat anti-rabbit IgG (GAR-HRP) at a dilution of 1:3000 at 4°C. for 16 hours. Color was developed with 4-chloro-1-napthol for 3-5 minutes and reactions were then terminated by serial washings in distilled H 2 O. Second and third screens were performed at 10-fold and 100-fold less phage per plate to identify isolated plaques.
  • GAR-HRP horseradish peroxidase conjugated goat anti-rabbit IgG
  • a second oligonucleotide probe was synthesized corresponding to the reverse translation of the 9 amino acids of the NH 2 -terminal sequence of human SAP(Phe) seen in Table 2.
  • the sequence of this probe was 5'-CCAICAITAIGGIATIGGIATIGGIAA-3', where I stands for deoxyinosine.
  • the positive clones selected with bovine surfactant polyclonal antisera were plated out by spotting 1 ul of a phage supernatant on a lawn of E. coli strain Y1090 ( ⁇ lac U169 pro A + Ion ara D139 strA supF ⁇ trpC 22:Tn10 ⁇ pMC9) (Clontech Laboratories, Palo Alto, California). The plates were incubated at 42°C. for 5-6 hours and then removed and overlaid with nitrocellulose filters.
  • the filters were then baked for 1 hour at 80°C. in a vacuum oven. Filters were prehybridized for 6 hours at 45°C.
  • prehybridization buffer 5 X SSPE, 5 X Denhardt's, 50 mM sodium phosphate pH 7.0, 1 mM sodium pyrophosphate, 100 uM ATP, 50 ug/ml boiled salmon sperm DNA. While the filters were prehybridizing, the SAP (Val) oligonucleotide probe described in Example 6 was end-labeled with T 4 polynucleotide kinase and ⁇ - 32 P-ATP essentially as described by Maniatis et al., "Molecular Cloning; A Manual," Cold Spring Harbor, New York (1982).
  • the SAP(Val) probe was added to the prehybridization buffer at a concentration of approximately 12 ng/ml, the filters were added, and incubated at 30°C. overnight. The filters were then washed in 0.2 X SSPE, 0.1% sodium dodecyl sulfate (SDS) at room temperature for 30 minutes, then at 32°C. for 45 minutes in fresh wash solution. They were then air- dried and subjected to autoradiography. This procedure was repeated with a second set of filters using the SAP (Phe) probe described in Example 6.
  • SDS sodium dodecyl sulfate
  • Hybridization was done in 6 X SSPE, 1 X Denhardt's, 50 ⁇ g/ml boiled salmon sperm DNA with a probe concentration of 1.5 ng/ml.
  • the filters were hybridi zed at 55°C . for 1 hour then overnight at 37°C. They were washed in 6 X SSPE 2 times at room temperature and then 2 times at 37°C. Clones found to hybridize to the probe on both sets of filters were isolated and purified by replating and screening at lower densities.
  • This clone was subcloned into an M13 sequencing vector (described by Messing et al., Methods in Enzymology, 101, 70-78 (1983) and sequenced using M13 oligonucleotide primers according to standard methodologies as described by Sanger et al., Proc. Nat'l Acad. Sci. (USA), 74, 5463-5467 (1977).
  • E. coli JM103 of JM109 (Pharmacia, Inc., Piscatawy, NJ) were used for growth of pUC plasmid and M13 phage subclones.
  • the sequence of this SAP(Phe) clone is shown in FIG. 3. Underlined in this figure is the region which corresponds to the NH 2 -terminal amino acid sequence for human SAP (Phe) shown in Table 3.
  • Nucleotide sequence analysis of one SAP (Val) clone, designated 334.2, of 0.3 kilobases comprised an open reading frame predicting close identity to the amino acid sequence determined directly from the human protein and was used to isolate other clones from the same cDNA library, as illustrated in FIG. 4. Sequence analysis of nine unique clones resulted in a consensus sequence predicting a larger polypeptide precursor.
  • clone 334.2 is the initial SAP (Val) isolate and was used as a probe for re-screening of the cDNA library.
  • Clones 311.3 and 13-1 have an 18 base pair deletion not seen in clones TP9-1 and TP11-2.
  • a notched box indicates the valine rich hydrophobic domain of SAP(Val) clones; "A" denotes
  • the nucleotide sequence was determined using overlapping cDNA clones 311.3, 13-1, TP11-2, TP9-1 and RJ2-1.
  • the broken under line indicates sequence from mRNA directed dideoxy sequencing using RJ2-1 as a primer that is present from sequence of the first exon of the SAP (Val) genomic clone VG519.
  • Solid underlined amino acid sequence obtained directly on human SAP (Val) protein. The predicted sequence and obtained sequence match at 16 or 17 amino acids, the difference being His 32 instead of Asn.
  • Overlined DNA sequence is the 18 bp sequence that is absent in cDNA clones 311.3 and 13-1.
  • RNA sequencing and analysis of genomic DNA were therefore utilized to predict the complete SAP(Val) mRNA.
  • a direct nucleotide sequence of SAP(Val) RNA was derived from human lung RNA. Dideoxynucleotide RNA sequencing was done by a modification of one procedure described by Ge Kunststoffter et al., Proc. Nat'l Acad. Sci. (USA), 83, 3371-3375 (1986).
  • An oligonucleotide primer specific for the 5' terminus of SAP(Val) cDNA was synthesized and end-labelled.
  • Poly (A) + mRNA (6 ⁇ g) and [ 32 P] labelled primer (5 ng) were heated at 80°C for 3 minutes in 10 ⁇ l of annealing buffer (0.25 M KC1, 10 mM Tris, pH 8.3) and then allowed to anneal for 45 minutes at 50°C.
  • annealing buffer (0.25 M KC1, 10 mM Tris, pH 8.3
  • RNA template:primer solution (2 ⁇ l) was added to 3.3 ⁇ l of transcription buffer (24 mM Tris pH 8.3, 16 mM MgCl 2 , 8 mM dithiothreitol, 0.4 mM dATP, 0.4 mM dCTP, 0.4 mM dTTP, 0.8 mM dGTP, 100 ⁇ g/ml actinomycin D) containing 5 units of AMV reverse transcriptase (Amersham) and 1 ⁇ l of one dideoxynucleotide triphosphate (0.5 mM ddGTP, 0.285 mM ddATP, 1.0 mM ddTTP, or 0.15 mM ddCTP). The reactions were incubated at 50°G for 45 minutes, heated at 80°C for 3 minutes in loading buffer (10 mM EDTA, 0.2% bromphenol blue, 0.2% xylene cyanol in 100% formamide), then loaded onto a sequencing gel.
  • the SAP(Phe) cDNA clones isolated by antibody screening and oligonucleotide hybridization were incomplete on the 5' and 3' ends.
  • Several of these cDNA clones were used as hybridization probes to isolate additional cDNA clones from the library. Sequence analysis of one of these clones showed it to be complete on both 5' and 3' ends. This sequence is shown in FIG. 6.
  • the SAP(Phe) transcript encodes a precursor protein of approximately 42 kilodaltons.
  • S1 nuclease mapping was performed using with a fragment from the 5' end of the SAP(Phe) genomic clone described in Example 11. Probes were prepared and S1 nuclease protection was done by the method of Kay et al., Mol. Cell. Biol. 6, 3134-3143 (1986). In addition, adult human lung poly(A) + RNA was sequenced directly as described above. Both the S1 mapping and the direct RNA sequencing identified the 5' end as shown in FIG. 6. The hydrophobic regions of SAP(Phe) and SAP(Val) as shown in FIGS. 3 and 5 in parentheses are somewhat homologous. Although these two proteins are encoded by distinct genes, it is believed that they are structurally related. Therefore, these proteins may be members of a family of related proteins which bind phospholipids and are useful in surfactant replacement therapy and diagnosis.
  • the SAP (Phe) cDNA clone shown in FIG. 3 was inserted into the EcoRI site of plasmid pUC9 in the same orientation as the lacZ gene.
  • the reading frame was then altered by cutting the plasmid DNA with the restriction enzyme Sail, then filling in the ends with T 4 polymerase and deoxynucleotides. This resulted in the insertion of 5 nucleotides within the lacZ gene upstream from the site of the fusion with the SAP (Phe) cDNA.
  • This led to the production of a lacZ/SAP(Phe) fusion product, which contains approximately 2400 daltons of lacZ at the NH 2 -terminal end of the SAP(Phe) gene product.
  • FIG. 7 shows a schematic diagram of this construction.
  • E.coli strain JM109 containing the plasmid described in Example 9 was grown up at 37°C. until the optical density at 600 nm reached 0.5, then IPTG was added to a concentration of 1 mM. The cells were grown for an additional 3-4 hours at 37°C. then pelleted and resuspended in 1/15th volume lysis buffer (62.5 mM Tris pH 6.8, 2% SDS, 10% glycerol, 5% ⁇ -mercaptoethanol, 0.1 mg/ml bromphenol blue).
  • the nitrocellulose filter was preblocked in TBS containing 50 gm/1 powdered milk at room temperature for 1 hour, then incubated with the preabsorbed antisera described in Example 5 at a dilution of 1:1000 at room temperature overnight. After this, the filter was washed 2 times in TBS, then incubated with GAR-HRP at a dilution of 1:2000 for 1 hour at room temperature.
  • FIG. 7 shows results of this test.
  • Lane B contains the lacZ/SAP(Phe) fusion protein
  • lane A contains protein from cells containing the plasmid which had not undergone the fill-in as described in Example 9.
  • the SAP(Phe) antisera of Example 5 recognized proteins of 32,000-34,000 daltons in molecular weight which is in agreement with the predicted size of the translation product from the open reading frame of the SAP (Phe) clone plus the 2400 dalton portion of lacZ.
  • a human embryonic kidney cell genomic library was constructed in the ⁇ vector EMBL3 [Frischholz et al., J. Mol. Biol., 170, 827-842 (1983)]. DNA isolated from these cells was partially digested with Mbol, size selected in an agarose gel for fragments larger than 20 kb, and ligated into the BamHI site of the ⁇ vector. This library was screened with hybridization probes made from SAP (Phe) cDNA clones. The SAP (Phe) cDNA probes were labeled by the random oligonucleotide primer labeling technique using a kit purchased from Pharmacia, Inc. (Milwaukee, Wisconsin). The library was plated on E.
  • coli strain NM539 at a density of 40,000 pfu per plate then blotted to nitrocellulose filters.
  • FIG. 8A shows the structure of the SAP(Phe) gene.
  • FIG. 8B shows a nucleotide sequence for genomic SAP(Phe) DNA obtained by standard sequencing techniques known to those skilled in the art.
  • S SacI; filled areas are translated regions of exons and cross hatched areas are untraslated regions of exons.
  • genomic sequences further the ability to clone and express SAP(Phe) genes, e.g. by providing regulatory sequences which may be particularly useful for regulating expression.
  • a SAP(Val) cDNA designated 334.2 was labelled with ⁇ [ 32 P]dCTP using a nick translation reagent kit (Bethesda Research Laboratories Life Technologies, Inc., Gaithersburg, MD). This probe was used to screen a human lymphocyte genomic library in XEMBL3 (Clontech Laboratories, Inc., Palo Alto, California). Approximately 2 X 10 6 clones were screened at an initial plating density of 30,000 pfu per plate. The filters were screened in duplicate. The second and third screens were performed at 10 fold and 100 fold lower dilution, respectively. Phage DNA was prepared essentially as described by Maniatis et al., supra, 371- 372. To identify genomic fragments containing
  • SAP(Val) sequences, cDNA described above was used in Southern blot analysis of genomic DNA after digestion with various restriction endonucleases. Southern blot analysis was performed using random primer labelled probes labelled with the random primer labelling technique (Pharmacia, Inc., Milwaukee, Wisconsin) hybridized with the DNA in 5 X SSC, 5 X Denhardt's solution, 0.1% SDS at 65°C. The nitrocellulose filters were washed twice (5 minutes each) at room temperature in 2 X SSC, 0.1% SDS, then twice in 2 X SSC, 0.1% SDS at 65°C. and four times in 0.2 X SSC, 0.1% SDS at 65°C.
  • the 5' untranslated portion of the mRNA contains a potential initiation site which fits the criteria for a mammalian ribosomal binding site. There are two potential ATG start sites (bases 26 and 53) at the 5' end of the mRNA, the more 3' one most closely meeting selection criteria.
  • the deleted sequence is located at the start of exon 5 and is preceeded by six nucleo tides (TTCCAG) which are also found at the end of exon four. Sequences at the 5' proximal end of exon five show two sets of sequence that conform to an intron-exon splice site consisting of a 10-15 base pair polypyrimidine tract followed by the dinucleotide AG, signaling the end of intronic sequence.
  • the base pairs (CTCACTTCCTACATTCC) comprise a 17 base pair tract preceeding the AG of the major cDNA species.
  • a second sequence preceeds the AG at the end of the deleted 18 base pair sequence and may represent an alternate splice site to account for the two observed SAP(Val) cDNA clones. If splicing occurs by a scanning mechanism, then this downstream alternate site may be less favored and result in the minor species lacking the 18 bp of cDNA. Only two of the nine SAP(Val) cDNAs detected during cDNA cloning contained this 18 base pair deletion. In summary, it appears that the 18 bp cDNA deletion arises from alternative splicing. It remains possible that the 18 base pair deletion resides in an allele of the SAP(Val) genes not detected in the present study.
  • Restriction endonuclease mapping of twelve clones identified by hybridization with SAP(Val) cDNA clone 334.2 demonstrated two distinct patterns of DNA fragments. Seven clones were represented by clone ⁇ VG519 and five clones were represented by clone ⁇ VG524. Restriction endonuclease fragments containing SAP(Val) coding regions were identified by their hybridization with cDNA clone 334.2. A distinct 1.8 kb HindHI/EcoRI hybridizing fragment was identified in clone ⁇ VG519, while, a 4 kb Hindlll hybridizing fragment was identified in clone ⁇ VG524.
  • the restriction map and organization of the two SAP(Val) clones are represented in FIG. 9.
  • the first two lines are restriction endonuclease maps of ⁇ VG519 and ⁇ VG524 representing two classes of restriction enconuclease patterns identified from the genomic clones .
  • the third line is expanded from the second line and represents sequences in and near the gene for ⁇ VG524. Overbrackets identify sequences hybridizing to the SAP(Val) cDNA probe (exons 2-5).
  • An ApaL1 restriction site identifies the polyvaline domain.
  • Line C indicates the relative position of exons of SPL(Val). Open blocks indicate untranslated exons; dark blocks indicate translated exons.
  • flanking regions of the genomic clones contained restriction site differences identified with Smal, Hindlll, and BamHI restriction enzymes.
  • the overlined sequence TGACGTCA represents a potential cAMP recognition sequence; the sequences TCACCTCT and TATAA representing consensus promoter and sequences are overlined. Alternative donor/acceptor splice sequences are overlined at the 5' end of exon 5.
  • the differences in sequence between ⁇ VG519 and ⁇ VG524 are shown by asterisks, dashes, and letters above the ⁇ VG519 sequence representing nucleotide insertions, deletions or substitutions, respectively.
  • RNA directed sequencing was performed to identify the nucleotide sequence from the available cDNA sequence to the transcription initiation site. A strong reverse transcriptase stop was detected in the RNA- directed sequence analysis. It is inferred that this demonstrates the site of transcription initiation.
  • an oligonucleotide (3'-CAGCCAGATGGATGTGGGCAG-5') spanning the 5'-most cDNA and eight base pairs of extended RNA directed sequence was synthesized and used to analyze Southern blots of ⁇ VG519 and ⁇ VG524. Identical restriction fragment patterns were detected in both classes of genomic clones with this oligonucleotide after digestion with Kpnl and Kpnl/Hindlll.
  • the 1.8 kb Kpnl and 1.1 kb Kpnl/Hindlll fragments were sequenced and found to include nucleotide sequences from the 5'- most cDNA clone (clone RJ2-1) and the 5' nucleotide sequence derived from mRNA-directed sequence analysis.
  • a consensus promoter sequence TATAA was located 30 base pairs 5' to the predicted transcription initiation site in both clones. As used throughout the present application, distances are given with respect to the location of the 3' end of the sequence being discussed.
  • the sequence TCACCTCT nearly matches a consensus eucaryotic promoter sequence TCAATCT in 6 of 7 nucleotides Breatnach et al., Ann. Rev. Biochem., 50, 349 (1981). It was located 55 nucleotides upstream of the transcription initiation site.
  • a sequence, TGATGTCA was located 504 base pairs upstream from the transcription initiation site and matches the sequence TGACGTCA in 7 of 8 base pairs.
  • This latter element comprises a sequence previously associated with cAMP responsivity [Montminy et al., Proc. Nat'l Acad. Sci. (USA), 83, 6682-6686 (1986)]. Consensus sequences previously recognized as corticosteroid-responsive elements were not detected in these clones, although glucocorticoid enhanced SAP(Val) expression in organ culture of fetal lung.
  • the nucleotide sequence of ⁇ VG519 and ⁇ VG524 were entirely conserved in the amino acid coding region.
  • the genomic sequences were identical to the
  • SAP(Val) cDNA except for a single nucleotide difference in exon 5 in which leucine is encoded by CTG rather than the TTG observed in the cDNAs. Nucleotide differences were noted in only those exons encoding the 3' untranslated regions. Nucleotide sequence difference frequencies (1-2%) were similar in both introns and the 5' and 3' flanking sequences available for analysis (approximately 500 base pairs from the TATAA). The 5'- most fragment of ⁇ VG519 (600 bp Hindlll fragments) was not present in ⁇ VG524 by Southern blot hybridization, demonstrating a difference in flanking sequence in that region.
  • the nearly complete conservation of the nucleotide sequence in the exons, the small divergence in the introns, and the differences in restriction mapping of the 3' and 5' regions are most consistent with the interpretation that the SAP(Val) genomic clones represent two distinct gene loci encoding SAP(Val). However, these differences may be due to allelic variation.
  • the predicted amino acid sequence of the entire SAP (Val) precursor was deduced from the cDNA clones, RNA sequencing and the genomic DNA. The precursor comprises 188 or 197 amino acids depending on assignment of the N-terminal methionine (or 182 or 191 with the deletion) representing a 21,000 Dalton polypeptide.
  • SAP(Val) peptide begins at Gly 25 or Ile 26 and the domain including amino acids Leu 37 to Ser 61 is compatible with a membrane-associated or spanning domain of 25 amino acids. This region contains the repeated valine residues.
  • the precise C-terminus of SAP (Val) has not been identified directly and numerous attempts to isolate proteolytic or CNBr fragments of the canine or bovine proteolipid have been unsuccessful.
  • the N-terminal amino acid sequences of the bovine and canine proteolipid preparations was greater than 90% SAP(Val) in multiple determinations.
  • tyrosine and phenylalanine are present in the amino acid sequence of the small molecular weight hydrophobic surfactant protein, human SAP(Phe). Lack of phenylalanine and tyrosine also distinguishes SAP (Val) from SAP (Phe) and from small molecular weight surfactant proteins previously reported.
  • genomic sequences further the ability to clone and express SAP (Val) genes, e.g. by providing regulatory sequences which may be particularly useful for regulating expression.
  • SAP(Val) cDNA clones isolated by olignucleotide hybridization were incomplete on the 5' and 3' ends. Additional clones were isolated using. SAP(Val) cDNA for the hybridization probe. Several were found to be complete on the 3' end, but none on the 5' end. Two distinct classes of SAP (Val) cDNA were detected by sequence analysis, differing by the absence of 18 nucleotides in the 3' coding region of some cDNAs. The complete 5' sequence was determined by direct sequencing of adult human lung poly(A) + RNA and by S1 nuclease mapping of a 5' fragment from a SAP(Val) genomic clone as described for SAP(Phe). The complete sequence including the 5' end identified by these two methods is shown in FIG. 5. The SAP (Val) transcript encodes a precursor protein of approximately 21 kilodatons. EXAMPLE 14
  • a [ 32 P]-labeled SAP(Val) cDNA clone was hybridized to DNA obtained from the mouse-human chromosomal panels.
  • the [ 32 P]-labelled SAP(Val) clone was hybridized to mouse-human chromosomal hybrids containing all human chromosomes as previously characterized. Hybridization was only observed with hybrids containing chromosome 8.
  • RNA was prepared and isolated by oligo (dT) cellulose chromatography from a fetal lung at 19 weeks gestation and human adult lung.
  • Adult and fetal lung tissue was homogenized in buffer containing 4 M guanidine thiocyanate, 0.5% N-lauroyl sarcosine, 20 mM sodium citrate, 0.1 M ⁇ -mercaptoethanol and 0.1% antifoam A.
  • RNA was extracted by centrifugation through a cushion of 5.7 M cesium chloride [Hsu et al., J. Histochem. Cytochem., 29, 577-580 (1981)].
  • the RNA pellet was dissolved in water, extracted with phenol and chloroform, and precipitated with ethanol.
  • RNA in an aqueous solution was determined by optical density at 260 nm.
  • RNA 5 ⁇ g was separated on 1.2% agarose, 7% formaldehyde gels, transferred to nitrocellulose and hybridized [Weaver et al., J. Appl. Physiol., 61, 694- 700 (1986)] with [ 32 P]SAP(Val) DNA clone 334.2 (1.4 x 10° cpm/ml, approximate specific activity 4 x 10 8 cpm/ ⁇ g), washed and exposed to Kodak XAR-film at -70°C overnight.
  • RNA 11 detected an approximately 0.9 kilobase RNA, distinct from that of SAP(Phe) or SAP-35 [Glasser, Proc. Nat'l. Acad., Sci. (USA), 84, 4007-4011 (1987); and Whitsett et al., J. Biol. Chem., 262, 5256-5261 (1987)].
  • SAP(Val) RNA was less abundant in human fetal lung (approximately 19-20 weeks of gestation) than in adult lung. The finding that the RNA for SAP (Val) is developmentally regulated is consistent with the possible role of SAP(Val) in surfactant function required for perinatal adaptation to air breathing at birth.
  • a E. coli expression vector has been developed for expression of heterologous proteins as fusions with the E. coli protein CMP-KDO synthetase (CKS) [Goldman et al., J. Biol. Chem., 261, 15831-15835 (1986)].
  • This vector was deposited including a SAP (Val) insert as ATCC Deposit No. 67517, on September 29, 1987, with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852.
  • the plasmid is a derivative of pWMlll[Mandecki et al..
  • the CKS gene is under the control of a wild type lac operator and a modified lac promoter, designated lacP- T9-D. The -9 position has been changed from G to T, and there is a 1 nucleotide deletion in the spacer region between the -35 and -10 regions.
  • the plasmid also contains the trpA Rho-independent transcription terminator [Christie et al., Proc. Nat'l. Acad. Sci.
  • Coomassie brilliant blue is illustrated in which: lane 1 contained pre stained high molecular weight standards (BRL Life Technologies, Gaithersburg, Maryland); lane 2 contains E. coli total cell lysate (no plasmid); lane 3 contains E. coli total cell lysate with CKS/SAP(Val) expressed; and lane 4 contains E. coli total cell lysate with CKS alone expressed.
  • a DNA fragment containing the SAP(Val) cDNA was inserted into the multiple cloning site of this vector at the 3' end of the CKS gene.
  • the two coding regions are in the same frame, so that expression results in a fusion protein containing the CKS protein and the entire SAP (Val) proprotein.
  • the fusion protein is 48.7 kDal; 27.4 kDal from CKS and 21.3 kDal from SAP(Val).
  • the CKS/SAP(Val) protein represents approximately 2-5% of the total protein as shown in FIG.
  • the cells may be lysed by a variety of methods, one example being the use of lysozyme, sodium deoxycholate, and sonication as described in Marston et al., Bio/Technology, 2, 800-804 (1984).
  • the CKS/SAP(Val) protein is in the insoluble pellet and may be purified away from the bulk of the E. coli proteins.
  • the CKS/SAP(Val) protein represents >60% of the total insoluble protein as shown in FIG. 14, lanes 2 and 3.
  • lane 14 illustrates a 12.5% SDS-PAGE stained with Coomassie brilliant blue in which: lane 1 contains pre stained high molecular weight standards (BRL Life Technologies, Gaithersburg, Maryland) lane 2 contains 1 ⁇ l of insoluble protein preparation; lane 3 contains 5 ⁇ l of insoluble protein preparation; and the arrow indicates CKS/SAP(Val) fusion protein.
  • SAP(Val) active region similar constructions can be made using the SAP(Val) or SAP(Phe) active regions alone.
  • the SAP (Val) active region as encoded by nucleotides 100-222 of FIG. 5, may be assembled using synthetic oligonucleotides and inserted into the CKS expression vector. This construction can be designed with an AspPro at the N-terminus of the active region. Acid cleavage at this bond would generate SAP(Val) containing an extra Pro at the N-terminus.
  • the first 3 amino acids are Gly-He-Pro
  • one may replace the Gly-Ile with Asp such that acids cleavage would leave the SAP(Val) active region minus the first 2 amino acids.
  • An alternative cleavage method using hydroxylamine might also be employed.
  • SAP(Val) or SAP(Phe) genomic or cDNA may be inserted into, for example, a mammalian expression plasmid adjacent to the herpes simplex type I (HSV) thymidine kinase (tk) promoter.
  • HSV herpes simplex type I
  • tk thymidine kinase
  • 2.5M CaCl 2 is added to the mixture to a final concentration of 0.125 M while a gentle stream of air is bubbled through the mixture during the addition of the CaCl 2 and for an additional 30 seconds.
  • the DNA is then allowed to precipitate for 30 minutes at room temperature and then 0.5 mis of the DNA suspension is added to 25 cm 2 dishes of baby hamster kidney cells, for example, or other mammalian cells of choice.
  • the culture medium is removed, the cells washed 1 time with Eagle's medium containing 5% fetal calf serum (EC-5), and 1 ml 25% dimethyl sulf oxide (DMSO) in HeBS is added to each dish for 4 minutes at room temperature. The 25% DMSO is then removed, the dish is washed 2 times with
  • the cells are then incubated in EC-5. Twentyfour hours after addition of DNA, the cells are infected with HSV (10 pfu/cell) and the infection allowed to proceed for 48 hours.
  • the expressed SAP (Val) or SAP (Phe) protein is then isolated from the culture fluids by, for example, immunoprecipitation and assayed by, for example, SDS-PAGE.
  • SAP SAP
  • SAP(Val) may also be expressed in any suitable expression system well- known to those skilled in the art. Examples of such expression systems include E. coli. Bacillus, yeast. baculovirus or other mammalian cell expression systems.
  • the sequences shown in FIGS. 3, 5, 6, 8B and 10 indicate that the SAP(Phe) and SAP(Val) are derived from larger precursor proteins. It is believed, based upon a best current estimate of molecular weight of 7500 to 7800 daltons, that a 75-80 residue active portion of the larger precursor protein of SAP(Phe) is encoded by the nucleotide region shown in brackets in FIG. 6. Similarly, it is believed, based upon NMR (NOESY-COSY) analysis of bovine SAP(Val), that the active portion of the larger precursor protein of SAP (Val) is encoded by 120 or 123 nucleotides, depending upon assignment of N- terminus as He or Gly, respectively. This nucleotide region is shown in brackets in FIG. 5. Therefore, it should be apparent to those skilled in the art that expression of either SAP (Val) or SAP (Phe) may be accomplished through expression of the DNA encoding the larger precursor proteins followed by a processing step to further isolate the active portion of these proteins.
  • SAP (Val) or SAP (Phe) proteins are produced by a variety of approaches.
  • the region encompassing nucleotides 627-851 shown in brackets in FIG. 6 may be selected for expression of a 75 amino acid polypeptide which is homologous to SAP (Phe) at the NH 2 -terminal end and has an approximate molecular weight of 7500 daltons.
  • SAP(Phe) or SAP (Val) or portions of these genes can be made by chemical or enzymatic synthesis. Further, it should be apparent that deletion, substitution, or addition analogs of such genes or portions of such genes may be made by techniques well known to those skilled in the art. Therefore, it should be understood that SAP (Val) or SAP(Phe) genes or portions thereof, whether isolated from genomic or cDNA libraries or made by chemical synthesis, and the proteins arising from expression of these genes, are well within the contemplation of this invention.
  • This polypeptide was assembled on a resin support by stepwise solid phase synthesis (starting with the carboxy terminal residue) according to the general procedure described in Barany et al., The Peptides, 2 , Gross et al., eds., Academic Press, New York, 1284 (1980).
  • a BOC-L-Ile-OCH 2 -Pam resin was transferred to a reaction vessel on an Applied Biosystems Synthesizer, Model 430A.
  • Protected amino acids were coupled in a stepwise manner to the resin support by preformed symmetric anhydride chemistry, except in the case of arginine addition, wherein the DCC/HOBT protocol [Konig et al., Chem. Ber., 103, 788-798 (1970)] was employed.
  • the fully protected peptide-resin (790 mg) was allowed to swell in methylene chloride (CH 2 Cl 2 ) for 5 minutes.
  • the N ⁇ -Boc protecting group was removed using 60% trifluoroacetic acid (TFA)/CH 2 Cl 2 deprotection, CH 2 Cl 2 washes, 10% N,N-diisopropylethylamine (DIEA)/CH 2 Cl 2 neutralization and a final wash with CH 2 Cl 2 .
  • the resin was dried in vacuo.
  • the peptideresin so obtained was treated with 9 ml of anhydrous hydrofluoric acid (HF) to which 0.5 ml of p-cresol and 0.5 g p-thiocresol had been added for 60 minutes at 0°C.
  • HF anhydrous hydrofluoric acid
  • the cleaved free peptide and resin were washed 3 times with 15 ml aliquots of diethyl ether, and the peptide was extracted by means of 3 extractions with 15 ml of 40% aqueous acetic acid.
  • the aqueous extracts were combined and washed three times with 10 ml aliquots of diethyl ether, whereupon the aqueous layer was lyophilized to provide the crude polypeptide for purification.
  • the crude polypeptide was purified by reversed-phase HPLC on C 4 columns employing gradients of 0.1% TFA/water (A) and 100% acetonitrile (B) as the solvent systems at a 1 ml/min flow rate for the analytical (Vydac-214-TP54, Vydac Separation Group, Hesperia, California) or 3 ml/min flow rate for the semi-preparative (Vydac-214-TP510).
  • the gradient was started with 30% B, and after one minute was linearly increased to 55% B over a period of 20 minutes before being reduced to 30% B over a period of one minute.
  • polypeptide was monitored at 225 nm and 280 nm.
  • the composition of the polypeptide was confirmed by hydrolysis in 6 N hydrochloric acid (HCl)/0.3% phenol at 150°C. for 2 hours in vacuo and was subsequently analyzed on a Beckman 6300 Amino Acid Analyzer.
  • a polypeptide having the following sequence having the following sequence,
  • NH 2 -Leu-Ile-Pro-Cys-Cys-Pro-Val-Asn-Ile-Lys-Arg-Leu-Leu- Ile-Val-Val-Val-Val-Val-Val-COOH was synthesized to provide a replica of the initial 22 NH 2 - terminal amino acid residues of bovine SAP (Val), and was assembled, purified and analyzed according to the procedure of Example 19, except that the aqueous layer was very turbid and immediately formed an emulsion during washing with ether. At this stage, the aqueous layer was centrifuged at 7500 rpm, 4°C., and a cake-like solid was obtained.
  • a polypeptide having the following sequence, NH 2 -Phe-Pro-He-Pro-He-Pro-Tyr-Cys-Trp-Leu-COOH was synthesized to provide a replica of the initial 10 NH 2 - terminal amino acid residues of human SAP(Phe) except that, at position 5, He was selected rather than Leu.
  • This peptide was assembled according to the general method of Example 19. Side-chain protecting groups employed for the synthesis were: Trp, CHO; Tyr, 2-Br-Z; and Cys, 4-MeBzl.
  • the fully protected peptide-resin (610 mg) was allowed to swell in CH 2 Cl 2 for 5 minutes and then the N ⁇ -BOC group was removed as described in Example 19.
  • the dried peptide-resin was treated with a mixture of anhydrous HF (2.5 ml):p-cresol (0.5 ml) :thiocres ⁇ l (0.5 g) :dimethylsulfide (DMS) (6.5 ml) for 60 minutes at 0°C. DMS and HF were distilled off in vacuo at 0°C.
  • HF a mixture of anhydrous HF
  • p-cresol 0.5 ml) :thiocres ⁇ l
  • DMS dimethylsulfide
  • the stepwise synthesis was then continued by using double coupling protocols on the remainder of the decapeptide-resin.
  • a first coupling protected amino acids were coupled by preformed symmetric anhydride in DMF.
  • a second coupling of symmetric anhydride was conducted in CH 2 Cl 2 .
  • the amino acid glutamine was coupled using the DCC/HOBT protocol referenced hereinabove.
  • indole 1%, w/v
  • ethanedithiol (0.1%, v/v) were added to TFA. It was this modified solution which was used for all subsequent removals of N ⁇ -BOC protective groups.
  • the weight of the dried peptideresin at the end of synthesis was 2.72 g.
  • Side chain functional groups of various amino acid residues were protected by the following groups: Tyr, 2Br-Z; Cys,
  • the fully protected peptide-resin (610 mg) was allowed to swell in CH 2 Cl 2 for 5 minutes.
  • the N ⁇ -BOC protecting group was removed using TFA containing 1% indole and 0.1% EDT as described before in Example 19.
  • the peptide-resin was then treated with 8.5 ml of anhydrous HF to which 1.0 ml p-cresol, 0.3 ml DMS and 0.2 ml EDT had been added for 60 minutes at 0°C.
  • the HF/DMS was distilled off in vacuo at 0°C.
  • the cleaved peptide and resin were washed 3 times with diethyl ether and then the peptide was extracted using TFA followed by precipitation as a white solid as described in Example 20.
  • the crude peptide so obtained was analyzed and purified by reversed-phase HPLC on a C 4 column (Vydac-214-TP54) employing 0.1% TFA/water and 100% acetonitrile as the solvent system as described before. However, for preparative purposes, the column used was Vydac-214-TP1022 at a flow rate of 12 ml/min. The gradient was started at 40% B, and, after 5 minutes was linearly increased to 85% over 20 minutes. The gradient was next reduced to 40% B in 2 minutes.
  • the presence of peptide was monitored at 225 nm and 280 nm.
  • the composition of the purified peptide was determined by acid hydrolysis (12 N HCl/TFA, 2:1, 5% thioglycolic acid) at 150°C for 4 hours in vacuo followed by analysis on a Beckman 6300 amino acid analyzer.
  • peptides based on the sequences given herein may be synthesized and tested by methods known to those skilled in the art. For example, peptides with sequences based on the hydropathicity profiles disclosed herein, as well as those based on the secondary or tertiary structures of SAP(Phe) or SAP(Val) may be synthesized and tested for activity as generally described herein.
  • a fully protected peptide-resin was assembled on resin support by stepwise solid phase synthesis as described in Examples 19-22.
  • a Boc-L-Leu-OCH 2 -Pam-Resin was transferred to a reaction vessel.
  • the next 28 amino acids were coupled according to the standard single coupling protocol described before except for amino acids He and Val where double coupling protocols were used.
  • indole 1% w/v
  • ethanedithiol 0.25% v/v
  • stepwise synthesis was then continued on the rest of the peptide-resin using a double coupling protocol throughout the synthesis as described in
  • Example 22 A small amount of the peptide-resin was again taken out after incorporating amino acid Val at position 19. The weight of the dried peptide-resin at the end of the synthesis was 2.53 g. In this synthesis, methionine was used unprotected. However, it may be used in the protected form as a sulfoxide. Side chain functionalities of various amino acids were protected as described above. The amino acid His was protected by a Tosyl group. The integrity of the assembled peptide sequence on the resin was checked using solid phase sequencing as described before.
  • the N ⁇ -BOC protecting group was removed and then the peptide-resin was treated with 10 ml of anhydrous HF to which 1.0 ml of dimethylsulfide, 1.0 ml of p-cresol and 0.2 mg of thiocresol had been added for 60 minutes at 0°C.
  • the cleaved peptide and resin was washed 3 times with diethyl ether and then the peptide was extracted with 6 X 10 ml of 40% aqueous acetic acid.
  • the aqueous extract was lyophilized to yield the crude peptide. It was analyzed and then purified by reversed-phase HPLC on a C 4 column (D-04-1010, Lot-
  • the presence of peptide was monitored at 225 nm and 254 nm.
  • the composition of the purified peptide was determined by acid hydrolysis (12 N HCl:TFA,2:1) at 150° C for 4, 8 24 and 48 hours in vacuo in sealed tubes followed by analysis on a Beckman 6300 amino acid analyzer.
  • polypeptides according to present invention may be synthesized to the procedure as generally described in Examples 19-23.
  • the above polypeptides may have useful surfactant properties as described for the polypeptides of other Examples.
  • polypeptides according to present invention may be synthesized to the procedure as generally described in Example 23.
  • the above polypeptides may have useful surfactant properties as described for the polypeptides of other Examples.
  • SAP(Val) and/or SAP(Phe) Another utility for SAP(Val) and/or SAP(Phe) is in the preparation of antibodies or antisera . These antibodies or antisera may then be used for detecting, determining or purifying SAP(Val) and/or SAP(Phe). For example, antibodies and antisera may be used for immunoblot and ELISA analysis for immunological detection and quantification or other immunological assays. The detection and determination of SAP (Val) and/or SAP(Phe) by immunological methods is also of diagnostic importance.
  • SAP(Val) and/or SAP (Phe) antibodies and antisera were obtained as follows. Bovine lung lavage obtained as described in Example 1 was extracted and purified as described in Example 2, then dried and resuspended in ethanol. This suspension was mixed 1:1 with Freund's complete adjuvant and injected into albino rabbits. The rabbits were given injections at 4 separate sites, and usable antisera was obtainable after 3 sets of injections.
  • the bovine lung lavage used for injection contained monomers of SAP(Val) and/or SAP(Phe) and a smaller amount of the multimers of SAP(Val) and/or SAP ( Phe ) assessed by silver staining analysis after one dimensional SDS-PAGE. If desired, polyclonal antibodies may be further isolated from the antisera by affinity chromatography.
  • lymphocytes from mice immunized with isolated SAP(Val) and/or SAP(Phe) may be fused with mouse myeloma cells in the presence of, for example, polyethylene glycol, generally according to the technique of Kohler and Milstein, Nature, 256, 495-497 (1975), which is incorporated by reference herein.
  • the surviving hybrids may then be screened by solid phase ELISA to obtain only cells which produce the anti-SAP(Val) or anti-SAP(Phe) or antibody cross reacting with SAP(Val) and SAP(Phe).
  • MAbs may be employed in immunoassay techniques for detection of SAP(Val) and/or SAP(Phe) in, for instance, a tissue sample.
  • Such antibodies may bind to or precipitate SAP(Val) and/or SAP (Phe) from a mixture, may increase the sedimentation rate of SAP (Val) and/or SAP(Phe), may modify elution characteristics of SAP(Val) and/or SAP(Phe) on gel filtration, and may identify or quantify SAP(Val) and/or SAP(Phe) from a sample.
  • Polyclonal antibodies have been generated against the SAP(Val) and SAP(Phe) synthetic peptides described in Examples 19-21. These peptides were either injected directly or were first coupled with Keyhole Limpet Hemocyanin (“KLH”) (Calbiochem) using the bisdiazotized benzidine method of Bassini et al., Methods in Hormone Radioimmunoassay, Academic Press, 45-56 (1979). The peptides were combined 1:1 with Freund's complete adjuvant and injected into guinea pigs or albino rabbits 3 times at approximate intervals of 2 weeks. The first injection contained KLH, but subsequent injections did not. Approximately 1 mg of protein was injected each time.
  • KLH Keyhole Limpet Hemocyanin
  • SAP(Val) and SAP(Phe) are normally found in certain animal tissues, for example, lung tissue, lung lavage and amniotic fluid
  • a quantitative or qualitative measurement of SAP(Val) and/or SAP(Phe) may be used as a diagnostic, monitoring, or prognostic tool.
  • SAP(Val) and/or SAP(Phe) will not appear at or will appear in altered concentrations in the tissue of interest. For example, as shown in FIG.
  • polypeptides according to present invention may be synthesized to the procedure as generally described in Example 23.
  • the above polypeptides may have useful surfactant properties as described for the polypeptides of other Examples.
  • Active proteins human SAP(Val) and SAP(Phe) are derived from larger precursor proteins. Some peptides corresponding to sequences from precursor regions of the active proteins may be synthesized generally according to the procedure described in
  • Example 23 The following precursor peptides have been synthesized.
  • the above polypeptides may be used for the generation of antibodies for the recognition of precursor or active protein or some region thereof, and may have surfactant activity.
  • SAP (Val) or SAP (Phe) whether in monomeric or multimeric form or whether isolated from animal tissue or made by recombinant DNA methods or direct peptide synthesis based upon human or other animal nucleotide or amino acid sequences, is mixed with lipids, its surfactant-like activity is believed to impart to the mixture significant pulmonary biophysical surfactant activity.
  • Such a mixture with this activity is highly useful for replacing or supplementing natural pulmonary surfactant material for reducing or maintaining normal surface tension in lungs, especially in the lungs of animals suffering from HMD and other syndromes associates with the lack or insufficient amounts of natural pulmonary surfactant material.
  • isolated SAP(Val) and/or SAP(Phe) may be stored in chloroform under nitrogen or air at about -30° C prior to reconstitution with lipids. Preparations may also be made with alcohols.
  • Lipids including neutral or other lipids as well as phospholipids, employed in the preparations may be derived from a number of suitable phospholipids, such as phosphatidylcholine, disaturated phosphatidylcholine, phosphatidylglycerol, dipalmitoylphosphatidylcholine, phosphatidylinositol and mixtures thereof, cholesterol or cholesterol esters and mixtures thereof, and the like.
  • suitable phospholipids such as phosphatidylcholine, disaturated phosphatidylcholine, phosphatidylglycerol, dipalmitoylphosphatidylcholine, phosphatidylinositol and mixtures thereof, cholesterol or cholesterol esters and mixtures thereof, and the like.
  • purified SAP (Val ) and/or SAP ( Phe ) may be mixed in an amount of about 0.1 to about 2.0% with synthetic phospholipids, such as about 65% dipalmitoylphosphatidylcholine, about 20% phosphatidylglycerol, and about 10% palmitic acid.
  • the mixture may further contain a physiological buffer comprising 0.9% sodium chloride with or without about 0.5 to about 1.5 mM calcium chloride or any other suitable pharmaceutically accepted carrier.
  • the material may be sonicated or vortexed and tested for surface tension lowering capacity and adsorption of a Wilhelmy balance or other surface tension measuring devices. Adsorption studies may be conducted by the methodology disclosed by Notter et al., Chem. Phys. Lipids, 33, 67-80 (1983) and Ross et al., J. Biol. Chem., 261, 14283-14291 (1986) which are incorporated by reference herein.
  • Preparations for medicinal applications comprising SAP(Val) and/or SAP(Phe) and lipid may be prepared by methods apparent to those skilled in the art.
  • Various methods similar to those described by Yu, et al., J. Biochim. Biophys. Acta., 776, 37-47 (1984); Tanaka, et al., J. Lipid Res., 27, 475-485 (1986); Notter, et al., Ped. Res., 16, 515-519 (1982); Revak, et al., Am. J. Respir. Pis., 134, 1258- 1265 (1986) and Suzuki, et al., Eur. J. Respir. Pis., 69, 336-345 (1986) may be used to prepare mixtures of lipids, fatty acids, glycerol derivatives, cholesterol or cholesterol esters with monovalent or divalent metal ion salts and mixtures thereof.
  • lipid lipid
  • fatty acid triglycerides
  • triglycerides diglycerides
  • metal salt and neutral lipid classes in combination with the protein or peptide to prepare suitably active surfactants.
  • a suitable mixture may be comprised of 40-75% dipalmitoylphosphatidyl choline, 0-40% phosphatidyl glycerol, 0-5% cholesterol, 0-10% palmitic acid and 0- 10% tripalmitin with 0.1-10% SAP(Val) or SAP(Phe) protein. or peptide.
  • Preparation of such admixtures may be accomplished by dissolving the protein or peptide and selected lipid classes in the appropriate solvents, comixing these various solutions in the appropriate ratios, evaporating the solvents and dispersing the resulting admixture in an aqueous media appropriately buffered to physiologic conditions preferably with the chloride salts of mono- or divalent metal ions, e.g., sodium or calcium.
  • a protein or peptide is dissolved in a suitable solvent, e.g., chloroform, chloroform:methanol (2:1-5:1), formic acid (50-88%), trifluoroacetic (25-
  • dimethyl formamide or dimethylsulfoxide mixed with the necessary phospholipids, lipids, fatty acids, triglycerides, diglycerides, cholesterol and its esters which are dissolved in suitable solvents as described above under suitable conditions of time and temperature followed by solvent evaporation with warming to 35-75°C, either in vacuo or under an "inert,” e.g. nitrogen, gas.
  • the remaining protein lipid admixture is then dispersed with agitation in a variable speed vortex mixer or in an ultrasonic bath (Branson Ultrasonic Cleaner, Model B-32, Shelton, Connecticut) in an aqueous medium containing approximately physiologic concentrations of mono- or divalent metal salts, e.g., 0.9% sodium chloride and/or 1.5 mM calcium chloride to provide a uniform dispersion.
  • a variable speed vortex mixer or in an ultrasonic bath (Branson Ultrasonic Cleaner, Model B-32, Shelton, Connecticut) in an aqueous medium containing approximately physiologic concentrations of mono- or divalent metal salts, e.g., 0.9% sodium chloride and/or 1.5 mM calcium chloride to provide a uniform dispersion.
  • mono- or divalent metal salts e.g., 0.9% sodium chloride and/or 1.5 mM calcium chloride
  • a phospholipid mixture containing about 68% dipalmitoylphosphatidylcholine (DPPC), about 22% phosphatidylglycerol and about 10% palmitic acid is combined with delipidated SAP(Val) and/or SAP (Phe) and tested in a Wilhelmy balance.
  • the SAP(Val) and/or SAP(Phe) phospholipid mixture reduces the surface tension to less than 5 dynes/cm 2 , is adsorbed rapidly and is found to be more active than the phospholipid mixtures.
  • SAP(Val) and/or SAP(Phe) are believed to have useful "surfactant-like” or “surfactant-associated” activity.
  • surfactant-like or “surfactant-associated” activity.
  • surfactant-associated activity refers to the ability to interact with phospholipids, lipids and other materials described to reduce surface tension at a surface or reduce surface tension at an air-liquid interface. And when SAP (Val) and/or SAP(Phe) whether in monomeric or multimeric form, or whether isolated from animal tissue or made by recombinant DNA methods or direct peptide synthesis, is mixed with lipids, its surfactant-like or surfactant-associated activity is believed to impart to the admixture significant biophysical surfactant activity.
  • Such a mixture with such activity is highly useful for replacing or supplementing natural pulmonary surfactant material to reduce or maintain normal surface tension in lungs, especially in the lungs of animals suffering from HMD and other syndromes associated with the lack or insufficient amounts of natural pulmonary surfactant material.
  • Basic characteristics of a suitable surfactant preparation are the ability of the surfactant to adsorb from the subphase to the fluid-air interface and to reduce the surface tension at the interface under dynamic compression and expansion of the surface area.
  • Two common methods of measuring surface tension under dynamic conditions are the Pulsating Bubble Surfactormeter (PBS) [Enhorning, J. App. Physiol. 43, 198-203 (1977)] and by the use of a modified Wilhelmy Surface Balance (“WSB”) [Notter, in Pulmonary Surfactant, Ch. 2, Robertson et al., eds, Elseiver, The Netherlands (1984)]. Either method provides similar information but the modified WSB is considered to provide more detail of the surfactant behavior.
  • Substantial reduction of surface tension under the experimental conditions specified is a prerequisite to proper in vivo activity. The time course of the adsorption from the subphase and the equilibrium surface tension which results also assists in providing a measure of activity of surfactant preparations.
  • phosphatidyl glycerol (Sigma Chemical Co.) at a concentration of 10 mg/ml in chloroform was used directly, 12.5 mg of cholesterol (Sigma Chemical Co.) was dissolved in sufficient chloroform to provide a stock solution of 0.25 mg/ml concentration, 33 mg of palmitic acid (Sigma Chemical Co.) was dissolved in a sufficient quantity of chloroform:methanol (2:1) to provide a stock soluton of 3.3 mg/ml concentration, and 33 mg of tripalmitin (Sigma Chemical Co.) was dissolved in sufficient chloroform:methanol (2:1) to provide a stock solution of 3.3 mg/ml concentration.
  • dipalmitoylphosphatidyl choline stock solution (15.5 mg of dipalmitoylphosphatidyl choline) 0.4 ml of the cholesterol stock solution (0.1 mg of cholesterol), 0.42 ml of the palmitic acid stock solution (1.4 mg of palmitic acid) and 0.42 ml of the tripalmitin stock solution (1.4 mg of tripalmitin) were added to the protein-phosphatidyl glycerol solution mixture, mixed briefly on a variable speed vortex mixer for 30-60 seconds and the solvents evaporated invacuo with warming to 45°C. until all traces of solvents had disappeared.
  • Table 4 of surfactant admixtures were obtained by use of the modified WSB.
  • the WSB is operated with a 0.9% sodium chloride solution as subphase at a temperature of 37°C, expanded and compressed over a 2.5-fold surface area at approximately 3 minutes/cycle with approximately 1.5 micrograms of phospholipid admixture per square centimeter of surface area of the subphase being added.
  • minimum surface tensions of less than 10 dynes/cm 2 after several cycles will be observed for a reasonably performing surfactant dispersion.
  • surface tension maximums will be less than 45 dynes/square centimeter and the percent area at which the surfactant exhibits surface tension of 10 dynes/square centimeter will be a 60% or greater expansion.
  • the adsorption data in Table 4 were obtained by a method similar to that of Notter et al., Chem. Phys. Lipids, 33, 67-80 (1983).
  • the electrobalance, sensor plate and incubator from the modified WSB are used.
  • the 0.9% sodium chloride solution subphase is stirred and approximately 5 mg of the admixture preparation diluted in a subphase solution volume is added.
  • Surface tension is monitored continuously with time as the admixture adsorbs to the subphase surface.
  • adsorption measurements which yield surface tensions of 35 dynes/cm 2 or less within 10-20 minutes indicate usable surfactants.
  • DPPC Dipalmi toy Iphosphat idyl Choline
  • PG Phosphatidyl Glycerol
  • PA Palmitic acid
  • TP Tripalmitin. It is shown in Table 4 that proper addition of protein or peptide to lipid mixtures modifies substantially the characteristics of the adsorption and dynamic surface tension diagrams in comparison to the lipid mixture or its individual components. This is demonstrated for protein isolates as well as for the synthesized peptides as shown in Table 4.
  • Hydropathy analysis was performed on the entire predicted amino acid sequences of SAP(Val) according to the procedure of Kyte and Doolittle [Feinberg et al., Anal. Biochem., 132, 6-13 (1983)] and results are presented in FIG. 18. Hydrophobicity is plotted as a function of residue number from Met 1 to the C-terminus, Ile 197 . Values indicating hydrophobic and hydrophilic regions are above and below 0.5 respectively as indicated by the horizontal dotted line.
  • hydropathy plots of SAP(Val) and SAP (Phe) demonstrate some features in common and there is structural similarity between the N-terminal primary amino acid sequence of SAP(Val) and SAP(Phe). Some of the difference between the two peptides in the valinerich area may be accounted for by single nucleotide sequence changes suggesting a close relationship between these surfactant peptides. It is of interest that only the hydrophobic regions of SAP (Val) and SAP (Phe) are structurally similar; there is little or no homology between the amino acid or nucleotide sequences flanking the "active" hydrophobic domain.
  • both SAP(Val) and SAP(Phe) support their hydrophobic interactions with surfactant phospholipids and clarification of their structures may therefore provide insight into the nature of their ability to impart surface activity to surfactant phospholipids.
  • Solubility in organic solvent systems and the marked hydrophobicity of both SAP(Val) and SAP(Phe) are properties similar to those classically referred to as proteolipids and are consistent with previous descriptions of hydrophobic proteins in porcine, rat and bovine surfactants. Extensive dialysis of the hydrophobic surfactant protein preparations results in protein with little remaining phospholipid; however, whether covalent phospholipids are associated with the protein has not yet been fully established. It is believed that the hydropathy plot generated using SAP(Val) amino acid sequence data according to the present invention permits the selectin of substitution, deletion and addition analogs of SAP(Val) on the basis that the hydropathy plot of the analog is substantially similar to that in FIG. 16.
  • Type II cells or sub-confluent 3T3 cells were incubated for three hours with multilamellar vesicles prepared by sonicating 200 ⁇ g of phospholipid with 1 ml of phosphate buffered saline (PC:DPPC:PG:PI, defined as in Example 32 above and in ratios of 10:35:7.5:7.5, w:w:w:w) and diluted with 8 ml of DMEM. As a tracer, 0.25 ⁇ Ci of [ 14 C]DPPC was included. At the end of three hours, cells were washed twice with unlabelled medium. and radioactivity was determined by liquid scintillation counting. Uptake was determined as ⁇ g phospholipid/mg DNA, and results expressed relative to the control as 100%. Peptides were present at a molar ratio of 1:11 (protein:phospholipid). Control is the uptake of labelled phospholipid by Type II cells in the absence of added peptide.
  • PC:DPPC:PG:PI phosphate buffered
  • mixtures containing SAP(Val) and/or SAP (Phe) and naturally occurring or synthetic lipids may be instilled intratracheally, for instance, in liquid form or as an aerosol spray in doses of about 0.01% to about 5.0% SAP(Val) and/or SAP(Phe) by weight, with about 20 to about 100 mg phospholipid per kilogram for treatment or prevention of HMD and other related disorders.
  • the present invention may, of course, be carried out in other specific ways than those herein set forth without departing from the spirit and essential characteristics of the invention. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive and all changes coming within the meaning and of equivalents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)

Abstract

De nouvelles protéines isolées, sensiblement pures, associées à un agent tensioactif hydrophobe et ayant un poids moléculaire simple compris entre 4000 et 7000 dalton, SAP(Val) et SAP(Phe); leurs multimères, et des analogues de substitution, d'addition et de délétion ainsi que leurs fragments sont décrits. Lorsque SAP(Val) et/ou SAP(Phe) est combiné avec des lipides, sa caractéristique de ressemblance à un agent tensioactif confère à la combinaison une activité biophysique pulmonaire importante. Une telle combinaison a pour résultat une adsorption augmentée des lipides avec des propriétés similaires à celle d'un matériau tensioactif pulmonaire naturel. SAP(Val) et/ou SAP(Phe) en combinaison avec des lipides est extrêmement utile pour remplacer ou compléter le matériau tensioactif pulmonaire naturel dans le but de réduire ou maintenir la tension en surface normale dans les poumons, en particulier dans les poumons de patients souffrant de maladie des membranes hyalines, HMD, ou d'autres syndromes associés à la carence ou à des quantités insuffisantes de matériau tensioactif pulmonaire naturel. Une combinaison de SAP(Val) et/ou SAP(Phe) et de lipides peut être administrée sous la forme d'une pulvérisation ou d'une solution saline aqueuse normale avec ou sans chlorure de calcium pour le traitement ou la prévention de HMD et d'autres états de déficience d'agent tensioactif. Sont également décrits des procédés d'isolement de SAP(Val) à partir de tissus animaux et des procédés de production de SAP(Val) et SAP(Phe) par des techniques d'ADN recombinant et synthèses directes de peptides; des clones génomiques de SAP(Val) et SAP(Phe); des produits et des systèmes d'expression pour SAP(Val) ADN; et des anticorps polyclonaux et monoclonaux contre SAP(Val) et SAP(Phe).
PCT/US1987/002536 1986-10-24 1987-10-02 Proteines associees a des agents tensioactifs hydrophobes pulmonaires WO1988003170A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
PCT/US1986/002258 WO1987006943A1 (fr) 1986-05-06 1986-10-24 Proteine associee a un agent tensio-actif hydrophobe pulmonaire d'un poids moleculaire de 6000 daltons, et ses multimeres
USPCT/US86/02258 1986-10-24
US93920686A 1986-12-08 1986-12-08
US939,206 1986-12-08
US6071987A 1987-06-10 1987-06-10
US60,719 1987-06-10
US10168087A 1987-10-01 1987-10-01
US101,680 1987-10-01

Publications (1)

Publication Number Publication Date
WO1988003170A1 true WO1988003170A1 (fr) 1988-05-05

Family

ID=27490143

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1987/002536 WO1988003170A1 (fr) 1986-10-24 1987-10-02 Proteines associees a des agents tensioactifs hydrophobes pulmonaires

Country Status (2)

Country Link
EP (1) EP0290516A4 (fr)
WO (1) WO1988003170A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000167A1 (fr) * 1987-07-01 1989-01-12 Kabigen Ab Proteines, compositions de proteines et leurs utilisations
EP0331961A2 (fr) * 1988-03-11 1989-09-13 Abbott Laboratories Procédé pour la production de protéines en utilisant de protéines fusionnées du type CKS
EP0350506A1 (fr) * 1988-01-06 1990-01-17 The Scripps Research Institute Proteine de tensio-actif pulmonaire et polypeptide s'y rapportant
EP0368823A2 (fr) * 1988-10-18 1990-05-16 Kabi Pharmacia AB Lipoprotéine biologiquement active et son emploi
EP0383837A1 (fr) * 1987-11-04 1990-08-29 Byk Gulden Lomberg Chemische Fabrik GmbH Proteines a effet tensio-actif alveolaire
EP0428615A1 (fr) * 1988-08-11 1991-05-29 California Biotechnology, Inc. Procede et vecteurs de stabilisation de l'expression de proteines heterologues
EP0458167A1 (fr) * 1990-05-21 1991-11-27 Abbott Laboratories Conjugés acide gras- tensioactif pulmonaire
US5238920A (en) * 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
AU650038B2 (en) * 1988-03-11 1994-06-09 Abbott Laboratories CKS method of protein synthesis
EP0635028A1 (fr) * 1992-04-10 1995-01-25 Abbott Laboratories Fragments proteiques tensio-actifs pulmonaires
AU682738B2 (en) * 1993-12-08 1997-10-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Novel synthetic peptide, lung surfactant containing the same, and remedy for respiratory distress syndrome
US5683982A (en) * 1991-11-04 1997-11-04 Merrell Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
US6372720B1 (en) * 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US6982075B2 (en) 2001-10-11 2006-01-03 Altana Pharma Ag Use of pulmonary surfactant
WO2010087771A1 (fr) * 2009-01-30 2010-08-05 Alphabeta Ab Composé et procédé de traitement de la maladie d'alzheimer
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
US8236750B2 (en) 2004-08-06 2012-08-07 Nycomed Gmbh Composition comprising a pulmonary surfactant and a TNF-derived peptide
US20140017815A1 (en) * 2011-03-25 2014-01-16 Roche Diagnostics Operations, Inc. MEASUREMENT OF C-TERMINAL proSP-B
US8785391B2 (en) 2010-06-24 2014-07-22 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
US9289388B2 (en) 2008-12-10 2016-03-22 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
US9522170B2 (en) 2011-04-05 2016-12-20 Alphabeta Ab Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016258A (en) * 1975-08-05 1977-04-05 Said Sami I Vasoactive intestinal peptide from fowl
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240550A4 (fr) * 1985-09-26 1989-09-19 Genetics Inst Proteines tensio-actives pulmonaires.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016258A (en) * 1975-08-05 1977-04-05 Said Sami I Vasoactive intestinal peptide from fowl
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biochemistry, issued 1985, Vol. 24, pages 184-190, (HAWGOOD) *
CHEMICAL ABSTRACT, Vol. 105, issued 1986, Abstract No. 94932s, (WHITSETT) "Immunologic Identification of a Pulmonary Surfactant-Associated Protein of Molecular Weight" *
See also references of EP0290516A4 *
The Journal of Biological Chemistry, issued 5 December 1985, Vol. 260, pages 15273, (WHITSETT) *
The Journal of Biological Chemistry, issued 5 July 1986, pages 9029, Vol. 261, (FLOROS) *
The Journal of Biological Chemistry, Vol. 261, issued 15 January 1986, pages 828-831 (FLOROS) *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000167A1 (fr) * 1987-07-01 1989-01-12 Kabigen Ab Proteines, compositions de proteines et leurs utilisations
EP0383837A1 (fr) * 1987-11-04 1990-08-29 Byk Gulden Lomberg Chemische Fabrik GmbH Proteines a effet tensio-actif alveolaire
EP0383837B1 (fr) * 1987-11-04 1998-02-04 Byk Gulden Lomberg Chemische Fabrik GmbH Proteines a effet tensio-actif alveolaire
EP0350506A1 (fr) * 1988-01-06 1990-01-17 The Scripps Research Institute Proteine de tensio-actif pulmonaire et polypeptide s'y rapportant
US5407914A (en) * 1988-01-06 1995-04-18 The Scripps Research Institute Pulmonary surfactant protein and related polypeptides
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
EP0350506A4 (en) * 1988-01-06 1992-01-22 Scripps Clinic And Research Foundations Pulmonary surfactant protein and related polypeptide
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
EP0331961A3 (en) * 1988-03-11 1990-07-04 Abbott Laboratories Method for protein synthesis using cks fusion proteins
AU650038B2 (en) * 1988-03-11 1994-06-09 Abbott Laboratories CKS method of protein synthesis
EP0331961A2 (fr) * 1988-03-11 1989-09-13 Abbott Laboratories Procédé pour la production de protéines en utilisant de protéines fusionnées du type CKS
AU625554B2 (en) * 1988-03-11 1992-07-16 Abbott Laboratories CKS method of protein synthesis
EP0428615A4 (en) * 1988-08-11 1991-11-13 California Biotechnology, Inc. Method for stabilizing heterologous protein expression and vectors for use therein
EP0428615A1 (fr) * 1988-08-11 1991-05-29 California Biotechnology, Inc. Procede et vecteurs de stabilisation de l'expression de proteines heterologues
EP0368823A3 (en) * 1988-10-18 1990-05-23 Kabigen Ab Biologically active lipoprotein and its use
EP0368823A2 (fr) * 1988-10-18 1990-05-16 Kabi Pharmacia AB Lipoprotéine biologiquement active et son emploi
US5455227A (en) * 1988-10-18 1995-10-03 Kabigen Ab Biologically active lipoprotein and its use
US5238920A (en) * 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
EP0458167A1 (fr) * 1990-05-21 1991-11-27 Abbott Laboratories Conjugés acide gras- tensioactif pulmonaire
US5683982A (en) * 1991-11-04 1997-11-04 Merrell Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
EP0635028A4 (fr) * 1992-04-10 1995-11-22 Abbott Lab Fragments proteiques tensio-actifs pulmonaires.
EP0635028A1 (fr) * 1992-04-10 1995-01-25 Abbott Laboratories Fragments proteiques tensio-actifs pulmonaires
US5827825A (en) * 1993-12-08 1998-10-27 Tokyo Tanabe Company Ltd. Synthetic peptide, lung surfactant containing the same and remedy for respiratory distress syndrome
CN1057099C (zh) * 1993-12-08 2000-10-04 三菱东京制药株式会社 新的合成肽，其中间体及其生产方法
AU682738B2 (en) * 1993-12-08 1997-10-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Novel synthetic peptide, lung surfactant containing the same, and remedy for respiratory distress syndrome
US6372720B1 (en) * 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US6982075B2 (en) 2001-10-11 2006-01-03 Altana Pharma Ag Use of pulmonary surfactant
US8236750B2 (en) 2004-08-06 2012-08-07 Nycomed Gmbh Composition comprising a pulmonary surfactant and a TNF-derived peptide
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
US9289388B2 (en) 2008-12-10 2016-03-22 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
WO2010087771A1 (fr) * 2009-01-30 2010-08-05 Alphabeta Ab Composé et procédé de traitement de la maladie d'alzheimer
US8785390B2 (en) 2009-01-30 2014-07-22 Alphabeta Ab Methods for treatment of Alzheimer's disease
US9402883B2 (en) 2009-01-30 2016-08-02 Alphareta Ab Compound and method for treatment of Alzheimer's disease
US8785391B2 (en) 2010-06-24 2014-07-22 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
US20140017815A1 (en) * 2011-03-25 2014-01-16 Roche Diagnostics Operations, Inc. MEASUREMENT OF C-TERMINAL proSP-B
US9522170B2 (en) 2011-04-05 2016-12-20 Alphabeta Ab Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein

Also Published As

Publication number Publication date
EP0290516A4 (fr) 1989-11-14
EP0290516A1 (fr) 1988-11-17

Similar Documents

Publication Publication Date Title
WO1988003170A1 (fr) Proteines associees a des agents tensioactifs hydrophobes pulmonaires
EP0210189B1 (fr) Proteine tensio-active alveolaire recombinante
EP0409472B1 (fr) Protéine morphogénétique d'origine osseuse
JP3017962B2 (ja) ヘマトクリット値を上昇させるための医薬組成物の製造方法
JP2869920B2 (ja) 組織因子タンパク質を製造するためのデオキシリボ核酸
AU616672B2 (en) Growth hormone receptor
AU650893B2 (en) O-glycosylated alpha-2 interferon
DK175703B1 (da) Human vævsfaktor-relaterede DNA-segmenter, polypeptider og antistoffer, hybridomaer, bestemmelsesmetoder, diagnostiske systemer og metoder, isoleringsmetoder og fremstillingsmetoder
Lusis et al. Cloning and expression of apolipoprotein B, the major protein of low and very low density lipoproteins.
EP0307513A2 (fr) Protéines hydrophobes pulmonaires à tensioactivité associée
US5019508A (en) Synovial phospholipases
US4912038A (en) Recombinant DNA sequence encoding alveolar surfactant protein
JP2004256541A (ja) インスリン様成長因子結合タンパク質とその組成物
US4933280A (en) Recombinant DNA sequence encoding Alveolar Surfactant Protein
AU612572B2 (en) Nucleic acid and methods for the synthesis of novel DAF compositions
JP3054092B2 (ja) 滑膜ホスホリパーゼ抗体
JP2004510426A (ja) 多発性硬化症の治療におけるケモカイン変異体
WO1990007937A1 (fr) Applications de proteines specifiques a la grossesse
WO1997027865A1 (fr) Antagonistes de la prolactine et leurs utilisations
KR100237582B1 (ko) Tpo 활성을 갖는 단백질의 제조방법
JP3232415B2 (ja) モノクローナル抗体，その製造法および用途
JPH09500017A (ja) 血小板糖蛋白ｖ遺伝子と使用
AU645965C (en) Pregnancy specific proteins applications
DK176220B1 (da) Monoklonalt antistof, som binder human vævsfaktor-protein, samt dets anvendelse
WO2000006731A2 (fr) La persephine arf, proteine codee par un arnm de persephine sans epissure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987907365

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987907365

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1987907365

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载